The quest for HIV vaccines
MODERATOR
Philipp Schommers
University Hospital Cologne, Germany
Share
10:30
3 min
Introduction
University Hospital Cologne, Germany
10:33
8 min
The HIV-1 Tat-based therapeutic vaccine to intensify or replace antiretroviral therapy: results of extended (8-years) follow.up of Phase-II clinical trials in Italy and South Africa
Istituto Superiore di Sanità (ISS), Italy
10:41
8 min
V2-specific responses rescues SIV vaccine efficacy decreased by mucosal immunization with nanoparticles
National Institutes of Health, United States
10:49
8 min
Safety and immunogenicity of a polyvalent DNA/polyvalent protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or co-administered in adults without HIV
University of Pennsylvania, United States
10:57
8 min
Potent and broadly neutralizing HIV-1 antibodies with improved pharmacokinetics achieved by negative supercharging
National Institutes of Health, United States
11:05
8 min
TCR repertoire diversity allows for differentiation of HIV-specific CD8 T cells following anti-PD1 in people with HIV and cancer on ART
Peter Doherty Institute, Univsersity of Melbourne, Australia
11:13
17 min
Q&A and conclusion
University Hospital Cologne, Germany
Istituto Superiore di Sanità (ISS), Italy
National Institutes of Health, United States
University of Pennsylvania, United States
National Institutes of Health, United States
Peter Doherty Institute, Univsersity of Melbourne, Australia